Skip to main content
. Author manuscript; available in PMC: 2010 Jul 2.
Published in final edited form as: Subst Use Misuse. 2009;44(2):253–281. doi: 10.1080/10826080802347677

Table 6.

Indication of Exposure to RAP Peer Intervention at Baseline (B) and Follow-up (F) (percentages within each category unless otherwise indicated)a

PHAs CRs Others b Total c
(B=112) (F=98) (B=222) (F=157) (B=188) (F=102) (B=522) (F=367)
Received from someone from
the RAP project in prior 6 mo.:
    Reading materials 14.0 65.2 4.3 50.9 7.6 35.2 7.9 51.1**
    Condoms 3.2 70.4 12.4 58.8 22.0 49.3 22.4 59.4*
    Other prevention materials 50.8 78.4 21.9 69.6 30.7 66.0 3. 71.9**
Received prevention info/
demo/materials from any active
drug user in the prior 6 mo.:
33.9 59.2 10.9 50.6 18.8 34.7 18.7 51.8*
    From someone you know 84.2 96.6 83.3 93.8 72.7 91.7 80.0 93.8
    From a stranger 36.1 44.2 26.1 38.5 56.3 35.3 40.7 39.3
    Where you usually use drugs 37.5 38.6 45.8 59.0 28.6 48.6 36.4 49.4
Recognized RAP Flip-book 18.9 100 8.2 64.9 9.3 46.5 11.9 69.6**
Number of RAP slogans ever
    heard at follow-up (mean) d
(4908) (2.096) (1.823) (2.790)**
Number of HIV/health issues
    talked about with other drug
    users in prior 2 wks (mean) e
(2.319) (5.638) (1.466) (2.555) (1.778) (2.196) (1.793) (3.293)**
a

Significance indicated is for baseline/follow-up comparisons in the total sample except in the absence of baseline comparisons. For that item, significance is indicated for the comparison between groups.

b

Includes all CRs of untrained PHAs (n=124 at baseline, n=76 at follow-up) and PHAs who never started the training (n=64 at baseline, n=26 at follow-up).

c

PHAs who attended 1–4 sessions (n=10) were included in the follow-up total.

d

Based on a total of six slogans. All slogans were translated into Spanish or replaced with Spanish equivalents. Slogans were not included in the baseline survey to reduce interview influence on this intervention exposure measure.

e

Based on a total of 14 talking items related to health, transmissible diseases, harm or risk reduction, and treatment.

*

p < .05;

**

p < .001